Dr Faith Howard
PhD, BSc (Hons).
Clinical Medicine, School of Medicine and Population Health
Postdoctoral Research Associate
Full contact details
Clinical Medicine, School of Medicine and Population Health
EU27, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
I joined the University of Sheffield in 2006 as a research technician where I completed a PhD in the Academic Unit of Nephrology in 2013 involving CDK/MEK inhibitors to inhibit fibrosis. In 2011 I joined the department of Clinical Oncology working on breast cancer and metastasis. I have multi-disciplinary, cross-sector experience having worked in industry between the years 2014-2018 in the AMR field before returning to the University of Sheffield and the study of breast cancer. My current research involves nanomedicine targeting of oncolytic viruses to metastatic tumours.
- Research interests
-
My research interests are focused on delivery of therapeutics to disseminated tumours. This includes nanoenabled formulations and the development of appropriate models for studying immunotherapies.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Inconsistencies in modeling the efficacy of the oncolytic virus HSV1716 reveal potential predictive biomarkers for tolerability. Frontiers in Molecular Biosciences, 9.
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
- Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
- Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
- Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
- Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
- Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
- Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
- Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 21(2), 327-341.
- Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models. Cellular Oncology, 36(6), 505-514.
- Seliciclib Inhibits Renal Hypertrophy but Not Fibrosis in the Rat following Subtotal Nephrectomy. Nephron Experimental Nephrology, 122(3-4), 114-122.
- Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Research, 14(3). View this article in WRRO
- Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis. PLOS ONE, 10(9), e0137321-e0137321. View this article in WRRO
Chapters
- Oncolytic viral particle delivery, Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
All publications
Journal articles
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology, 41(23), 3881-3890.
- Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116. View this article in WRRO
- Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharmacology, 2(4), 444-459.
- Understanding immune responses to viruses—do underlying Th1/Th2 cell biases predict outcome?. Viruses, 14(7).
- Inconsistencies in modeling the efficacy of the oncolytic virus HSV1716 reveal potential predictive biomarkers for tolerability. Frontiers in Molecular Biosciences, 9.
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
- Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology and Medicine, 40. View this article in WRRO
- Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
- Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1). View this article in WRRO
- Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
- Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
- Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.. Breast Cancer Research, 19.
- Interplay between transglutaminases and heparan sulphate in progressive renal scarring. Scientific Reports, 6(1). View this article in WRRO
- Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
- Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
- Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocrine-Related Cancer, 21(2), 327-341.
- Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models. Cellular Oncology, 36(6), 505-514.
- Seliciclib Inhibits Renal Hypertrophy but Not Fibrosis in the Rat following Subtotal Nephrectomy. Nephron Experimental Nephrology, 122(3-4), 114-122.
- Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Research, 14(3). View this article in WRRO
- Skin Gadolinium Following Use of MR Contrast Agents in a Rat Model of Nephrogenic Systemic Fibrosis. Radiology, 263(1), 107-116.
- P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.. Poster Session Abstracts.
- Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat. Investigative Radiology, 45(9), 507-512.
- Preferred Place of Death Discussions: Are They Informing and Empowering Patients and their Family Caregivers?. OMEGA - Journal of Death and Dying, 003022282211155-003022282211155.
- Inhibiting ERK Activation with CI-1040 Leads to Compensatory Upregulation of Alternate MAPKs and Plasminogen Activator Inhibitor-1 following Subtotal Nephrectomy with No Impact on Kidney Fibrosis. PLOS ONE, 10(9), e0137321-e0137321. View this article in WRRO
- Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid. Bone Abstracts.
Chapters
- Oncolytic viral particle delivery, Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
- Silk Fibroin Nanoparticles: A Biocompatible Multi-Functional Polymer for Drug Delivery, Biomedical Engineering IntechOpen
- Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer, Liposomes - Recent Advances, New Perspectives and Applications IntechOpen
Conference proceedings papers
- Research group
-
Member of Nanobug Oncology Sheffield (@Nanobug_Shef) team led by Dr Munitta Muthana.
- Grants
-
2022 British Association of Cancer, Roger Griffin Prize for Cancer Discovery.
2022 Early Career Researcher Prize for Outstanding Contribution to Research, Engagement and Leadership by Faculty of Medicine, Dentistry & Health, University of Sheffield.
2019 EPSRC NanoPrime Grant (EP/K005138/1A).
2018 CRUK New Investigator Committee - Research Travel Award.
- Teaching interests
-
I teach Immunology on the MBChB course and am module lead for Home Office Personal Licence holders. I also supervise research projects for the medical school MSc. Molecular Medicine and MSc. Translational Oncology courses.
- Professional activities and memberships
-
- Steering Committee member of the ECMC Junior Investigator Networking Group.
- Member of NCRI ECR Forum.
- Member of UKRI ECR Forum.
- Reviewer for ACS Nano, ACS Applied Materials and Interfaces, Advanced Therapeutics.